- Case Report
- Open Access
Cryptococcal meningoencephalitis in a patient with hyper immunoglobulin M (IgM) syndrome: a case report
© Malheiro et al.; licensee BioMed Central Ltd. 2014
- Received: 24 February 2014
- Accepted: 21 August 2014
- Published: 26 August 2014
Cryptococcal meningoencephalitis is an opportunistic infection that predominantly affects immunocompromised patients. Hyper immunoglobulin M syndrome is a primary immunodeficiency syndrome that increases susceptibility to several opportunistic infections. Here, we report a case of cryptococcal meningoencephalitis in the context of hyper immunoglobulin M syndrome, a situation that has been reported very few times and whose management is not clearly defined. We describe our management of this case and the outcome of the patient to help in future similar situations.
The patient is a 19-year-old Caucasian male student diagnosed with X-linked hyper immunoglobulin M syndrome and treated chronically with weekly intravenous immunoglobulin and daily sulfamethoxazole-trimethoprim. He was admitted to the infectious diseases ward because of headache, diplopia and a cerebral-spinal fluid analysis revealing cryptococcal meningoencephalitis. The patient was treated with liposomal amphotericin and flucytosine with a favorable outcome. Maintenance therapy with fluconazole has continued and will be sustained for 6 months following his upcoming bone marrow transplantation.
Monitoring for cryptococcal meningoencephalitis should be considered in patients with primary immunodeficiencies, as clinical manifestations may go unnoticed. In these patients, it is expected that chronic treatment with fluconazole will be the only treatment that will prevent reinfection or reactivation, and therefore should be kept at least until bone marrow transplant, the only curative treatment, is performed. It may, however, lead to intolerable side effects and hepatic toxicity.
- Hyper immunoglobulin M syndrome
- Cryptococcus neoformans
On April 29th 2013, a 19-year-old Caucasian male student was observed in the emergency department of our hospital complaining of diplopia, which started 2 weeks prior, and a mild frontal, bilateral, dull headache, persisting over the previous 2 days. He denied recently experiencing any fever, vomiting, nausea or any focal neurological signs. On physical examination, only a bilateral mild papillary border elevation was perceived by fundoscopy. Blood tests revealed the following measurements: hemoglobin, 14.8 g/dL; leucocytes, 9.02 × 109/L (neutrophils, 60%; lymphocytes, 21%); and platelets, 129 × 109/L. Blood chemistry showed normal renal and hepatic function, but with a C-reactive protein level of 17.3 mg/L (normal: <10 mg/L). The computed tomography (CT) scan of the patient’s brain was normal. A lumbar puncture (LP) was performed, which resulted in the release of clear cerebral-spinal fluid (CSF) and had an opening pressure of 33 cm H2O (normal: 7–14 cm H2O). Analysis of the CSF showed 120 leucocytes per cubic millimeter with 94.2% mononuclear cells, glucose levels <50% (43 mg/dL) of seric value (normal: >50% of seric value), and 0.87 mg/mL of proteins (normal: <0.5 mg/mL). The CSF cryptococcal antigen test was negative. The patient was treated empirically with ampicillin and ceftriaxone.
The patient’s medical history indicated that he had been diagnosed with X-linked HIGM syndrome at the age of 6 months in the setting of a severe Pneumocystis jirovecii pneumonia with secondary bronchopulmonary dysplasia. He has been treated chronically with weekly intravenous immunoglobulin (IVIg) and daily sulfamethoxazole-trimethoprim since 6 months of age. In spite of these treatments, he had several lower respiratory tract infections during childhood. His parents are asymptomatic, but his mother is a CD154 mutation carrier.
Following these findings, the empirical treatment with ampicillin and ceftriaxone was suspended and treatment with liposomal amphotericin and flucytosine was begun.
Two days later, a second CSF sample, with 104 leucocytes per cubic millimeter (57% lymphocytes and 7% neutrophils) and an opening pressure of 22 cm H2O was processed as described above. In this sample, the result from the India ink exam was positive and the yeast grown on the agar media were identified as Cryptococcus neoformans by Vitek MS™. The CSF cryptococcal antigen test was not repeated. The blood that had been collected upon admission was microbiologically negative.
The patient’s symptoms cleared after 7 days of treatment. Because of symptomatic improvement and the absence of increased intracranial pressure, regular evacuative LPs were not performed. After 2 weeks of treatment, a LP was repeated, yielding negative results from an India ink stain, Gram stain and culture. The cryptococcal serum antigen titer was 1:32. Treatment was changed to fluconazole (400 mg/day). During the length of his 18-day admittance, the patient maintained his usual prophylactic sulfamethoxazole-trimethoprim treatment and at discharge he was asymptomatic, with a normal physical exam. The patient remained on maintenance treatment for C. neoformans.
Cryptococcus neoformans is an encapsulated yeast found worldwide that is isolated predominantly from pigeon droppings and soil contaminated with avian excreta . It is not unusual for humans to come into contact with it early in life, and a majority of children are likely to have been exposed by the age of 5. This situation probably applies to our patient, as he was raised in a rural area.
Inhalation of the yeast is the most frequent way of acquiring this infection. From the lungs the fungal cells may spread hematogenously to the brain, causing life-threatening meningitis or meningoencephalitis, or even to other organs. The disease can vary from localized to disseminated and from acute to chronic depending on the state of the patient’s immune system, which may be impaired by malignancy, immunosuppressive therapies, or acquired/primary immunosuppression syndromes, as is the case for the patient described in this report.
There have been several attempts to gather information about X-linked HIGM syndrome, though its rarity makes the development of a comprehensive clinical picture of this disease hard to achieve.
X-linked HIGM syndrome is expected to increase susceptibility to C. neoformans, as it has been shown to do in vitro, although the in vivo incidence is not as great as expected, evidenced by the fact that only a few cases have been reported [5–8]. IVIg therapy, used widely in these patients from a young age, significantly decreases the frequency of lower respiratory tract infections and severe infections; however, it does not change the frequency of non-respiratory or upper respiratory infections .
In this patient the symptoms were less intense than expected. Clinically, there were no major central nervous system symptoms, apart from diplopia for far-sighted focus, which lasted for 2 weeks, and headache for the 2 days before admittance. There were no findings in his blood that suggested an infection, and if it were not for his medical history and high clinical suspicion, a LP would not have been performed. Nonetheless, a cerebral CT scan should always be done in a young patient presenting with headache and neurologic focal signs for a long period. This lack of symptoms may reveal a decreased immune response to Cryptococcus spp., as it was shown that in vitro the CD154-CD40 interaction is essential for the secretion of IL-12 and IFNγ in response to this organism . If these cytokines are not produced, the macrophages cannot activate T-cells through antigen-presenting dendritic cells, decreasing the rates of Th1 generation normally responsible for stimulating phagocytic activity towards fungal infections (Figure 1). As a consequence, the immune reaction will be less severe, with reduced immune activation and migration and fewer symptoms typically due to meningeal inflammation.
Amphotericin B and Flucytosine, suggested by current practice guidelines, were effective therapies against Cryptococcus neoformans as shown by the clinical improvement and the negative lumbar puncture after 2 weeks of combined treatment . Although this treatment was effective, there is no consensus on the appropriate duration for maintenance therapy. In the HIV setting, there is evidence that maintenance therapy should be kept until an immunologic improvement, characterized by CD4+ T-cells > 100/μL for more than 3 months, is achieved . However, in the X-linked HIGM setting, there is no evidence indicating whether to continue lifelong maintenance therapy or to stop after a short treatment. Patients with this disease are young, and lifelong therapy with fluconazole may lead to several side effects that can become intolerable and lead to hepatic toxicity. There are no methods, apart from bone marrow transplant (BMT), that can provide immune recovery for these patients; therefore, if they develop cryptococcal meningoencephalitis under treatment with IVIg, we expect that fluconazole will be the only treatment that will prevent reinfection or reactivation.
Recently, evidence that allogeneic BMT may lead to correction of the immunodeficiency, with varying degrees of success, has given new perspectives on this condition . Our patient has been recommended to undergo BMT and continue maintenance therapy with fluconazole until he is healthy enough to undergo the procedure. However, after the procedure he will be exposed to a new serious immunodepression because of the necessary post-transplant treatment with immunosuppressors, and a relapse of the disease is possible. There are recommendations for patients that develop cryptococcal meningoencephalitis during BMT, but none for patients with a previous history of the disease, so the choice to keep maintenance therapy for 6–12 months after the procedure is debatable.
X-linked HIGM syndrome is characterized by a high incidence of opportunistic infections with an unfavorable outcome, despite regular substitution therapy with IVIg. However, outcomes will likely be improved with additional therapies, like trimethoprim/sulfamethoxazole prophylaxis, and close follow-up. If these methods are successful, an older population of X-linked HIGM patients will develop in time, and new opportunistic infections that we are unaware of could also appear. Infections with Cryptococcus spp. may be more frequent than described and deserve further studies to determine treatment outcomes and duration.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We would like to thank Dr. Ben Sweeney, Dr. Ana Monteiro, Dr. Luís Afonso and Prof. Doutor Tiago Guimarães for providing medical guidance and writing services.
- Rosen FS, Kevy SV, Merler E, Janeway CA, Gitlin D: Recurrent bacterial infections and dysgammaglobulinemia: deficiency of 7S gamma-globulins in the presence of elevated 19S gamma-globulins. Report of two cases. Pediatrics. 1961, 28: 182-195.PubMedGoogle Scholar
- Fischer A: Primary immune deficiency diseases. Harrison’s Principles of Internal Medicine. Volume 2. Edited by: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. 2012, New York: The McGraw-Hill Companies, 2695-2706. 18Google Scholar
- Viviani MA, Tortorano AM, Ajello L: Cryptococcus. Clinical Mycology. Edited by: Anaissie EJ, McGinnis MR, Pfalle MA. 2003, Philadelphia: Churchill Livingstone, 240-259. 1Google Scholar
- Retini C, Casadevall A, Pietrella D, Monari C, Palazzetti B, Vechiarelli A: Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococus neoformans. J Immunol. 1999, 162: 1618-1623.PubMedGoogle Scholar
- Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME: The X- linked hyper-IgM Syndrome: clinical and immunological features of 79 patients. Medicine (Baltimore). 2003, 82 (Suppl 6): 373-384.View ArticleGoogle Scholar
- Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA, Tabone MD, Plantaz D, Etzioni A, Monafo V, Abinun M, Hammarstrom L, Abrahamsen T, Jones A, Finn A, Klemola T, DeVries E, Sanal O, Peitsch MC, Notarangelo LD: Clinical spectrum of X- linked hyper-IgM syndrome. J Pediatr. 1997, 131 (Suppl 1): 47-54.PubMedView ArticleGoogle Scholar
- Lee MY, Chung JH, Shin JH, Hwang TJ, Kim KS, Lee JH, Nam JH, Lee MC, Park CS, Juhng SW, Choi C: Lymphomodular cryptococcosis diagnosed by fine needle aspiration cytology in hyper-IgM syndrome. A case report. Acta Cytol. 2001, 45 (Suppl 2): 241-244.PubMedView ArticleGoogle Scholar
- Jo EK, Kim HS, Lee MY, Iseki M, Lee JH, Song CH, Park JK, Hwang TJ, Kook H: X- linked hyper-IgM syndrome associated with Cryptosporidium parvum and Cryptococcus neoformans infections: the first case with molecular diagnosis in Korea. J Korean Med Sci. 2002, 17 (Suppl 1): 119-620.Google Scholar
- Quartier P, Debré M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, Haddad E, Blanche S, Casanova JL, Smith CI, Le Deist F, de Saint BG, Fischer A: Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999, 134 (Suppl 5): 589-596.PubMedView ArticleGoogle Scholar
- Grewall IS, Xu J, Flavel RA: Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 1995, 378: 617-620. 10.1038/378617a0.View ArticleGoogle Scholar
- Perfect JR, Dismukes W, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010, 50 (Suppl 3): 291-322.PubMedView ArticleGoogle Scholar
- Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf]
- Tomizawa D, Imai K, Ito S, Kajiwara M, Minegishi Y, Nagasawa M, Morio T, Nonoyama S, Mizutani S: Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol. 2004, 76 (Suppl 1): 33-39.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.